Invention Grant
- Patent Title: N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
-
Application No.: US16244467Application Date: 2019-01-10
-
Publication No.: US10793562B2Publication Date: 2020-10-06
- Inventor: Inder Bhamra , Michael Mathieson , Craig Donoghue , Richard Testar
- Applicant: Redx Pharma PLC
- Applicant Address: GB Macclesfield
- Assignee: Redx Pharma PLC
- Current Assignee: Redx Pharma PLC
- Current Assignee Address: GB Macclesfield
- Agency: Foley Hoag LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@48d940a4 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5b6c8675
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D487/04 ; A61K31/497 ; A61K31/519 ; A61K45/06

Abstract:
Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
Public/Granted literature
- US20190144447A1 N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS Public/Granted day:2019-05-16
Information query